NAPROSYN Drug Patent Profile

When do Naprosyn patents expire, and when can generic versions of Naprosyn launch?

Naprosyn is a drug marketed by Atnahs Pharma Us and is included in two NDAs.

The generic ingredient in NAPROSYN is naproxen. There are forty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the naproxen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naprosyn

A generic version of NAPROSYN was approved as naproxen by GRANULES on December 21^st, 1993.

Summary for NAPROSYN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	106
Clinical Trials:	44
Patent Applications:	5,525
Drug Prices:	Drug price information for NAPROSYN
What excipients (inactive ingredients) are in NAPROSYN?	NAPROSYN excipients list
DailyMed Link:	NAPROSYN at DailyMed

See drug prices for NAPROSYN

Recent Clinical Trials for NAPROSYN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Northwestern Medical Group	Phase 2
Shirley Ryan AbilityLab	Phase 2
Western University, Canada	N/A

See all NAPROSYN clinical trials

US Patents and Regulatory Information for NAPROSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Atnahs Pharma Us	NAPROSYN	naproxen	SUSPENSION;ORAL	018965-001	Mar 23, 1987	AB	RX	Yes	No
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-004	Apr 15, 1982	AB	RX	Yes	Yes
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for NAPROSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-003	Approved Prior to Jan 1, 1982	3,904,682
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-004	Apr 15, 1982	3,998,966
Atnahs Pharma Us	NAPROSYN	naproxen	SUSPENSION;ORAL	018965-001	Mar 23, 1987	4,001,301
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-002	Approved Prior to Jan 1, 1982	4,009,197
Atnahs Pharma Us	NAPROSYN	naproxen	SUSPENSION;ORAL	018965-001	Mar 23, 1987	3,904,682
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-002	Approved Prior to Jan 1, 1982	3,998,966

International Patents for NAPROSYN

See the table below for patents covering NAPROSYN around the world.

Country	Patent Number	Title	Estimated Expiration
Switzerland	559161
Switzerland	549544	VERFAHREN ZUR HERSTELLUNG VON 2-(6-METHOXY-2-NAPHTHYL)1-PROPANOL.
France	1587861
United Kingdom	1301449
Spain	410167
Switzerland	556318	VERFAHREN ZUR HERSTELLUNG DER D-2-(6-METHOXY-2-NAPHTHYL)- PROPIONSAEURE. (2-(6-Methoxy-2-naphthyl) propionic acid prepns. - anti-pyretics, analgesics, anti-inflammatory agents)

Supplementary Protection Certificates for NAPROSYN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	1190013-1	Sweden		PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900	C300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
0984957	CR 2012 00035	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
1411900	122012000052	Germany		PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
1411900	300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17901/0263-001 20101105

Market Dynamics and Financial Trajectory for Naprosyn (Naproxen)

Last updated: January 10, 2026

Executive Summary

Naprosyn (generic: naproxen) is a non-steroidal anti-inflammatory drug (NSAID) widely used to treat pain, inflammation, and fever. Since its initial approval by the FDA in 1976, Naprosyn has established a robust commercial presence, especially within the chronic and acute pain management sectors. This analysis explores the market landscape, competitive forces, regulatory environment, and financial trajectory shaping Naprosyn’s future outlook.

Key highlights:

• The global NSAID market was valued at approximately $23.4 billion in 2021, projected to grow at a CAGR of 4.3% (2022–2028)[1].
• Naprosyn continues to command a significant market share; however, increased competition from both branded and generic NSAIDs and emerging biologics influence its positioning.
• Patent expirations, regulatory developments, and shifting prescribing patterns impact revenues.
• Increasing adoption of NSAIDs for osteoarthritis, rheumatoid arthritis, and gout supports sustained demand.
• The evolving landscape includes biosimilar entries and non-pharmacological therapies, challenging traditional NSAID sales models.

This report provides an in-depth assessment of market trends, revenue drivers, competitive dynamics, and future projections for Naprosyn.

---

What Are the Market Drivers Influencing Naprosyn?

1. Growing Prevalence of Chronic Pain and Inflammatory Conditions

According to the Global Burden of Disease Study 2019, musculoskeletal disorders account for 6.8% of total DALYs (Disability-Adjusted Life Years), with osteoarthritis, rheumatoid arthritis, gout, and other inflammatory conditions comprising significant patient populations[2]. The aging global population and sedentary lifestyles increase the demand for effective pain management, bolstering NSAID use.

2. Expanding Prescriptive and Over-the-Counter (OTC) Markets

Naproxen, available both as prescription (e.g., Naprosyn) and OTC formulations, benefits from broad accessibility:

• Prescription NSAIDs: Treat chronic conditions and severe acute pain.
• OTC NSAIDs: Widely used for minor pain, fever, and inflammation.

Recent regulatory shifts have facilitated OTC availability in many markets, especially for low-dose naproxen, influencing volume growth.

3. Innovations and Formulations

Advancements include sustained-release formulations, combination therapies, and novel delivery methods aiming to improve adherence and reduce gastrointestinal side effects.

4. Regulatory Landscape and Patent Expiry

Patents protecting Naprosyn formulations began expiring in various jurisdictions post-2010, opening avenues for generic competition:	Patent Expiration	Market Scope	Impact
US (2008–2012)	Major formulations	Increased generics, commoditization
EU (2010–2014)	Extended patent protections	Continued branded sales

Generic entry has historically reduced prices, pressuring branded sales but expanding overall market volume.

---

How Do Market Trends Affect Naprosyn's Financial Trajectory?

1. Revenue Landscape and Market Share

Revenue Factors	Impact on Naprosyn
Generic Competition	Drives down unit prices but increases sales volume over time
Prescribing Trends	Shift towards alternative NSAIDs or biologics could dampen growth
Price Regulations	Policy-driven price controls, especially in Europe and Asia
Reimbursement Policies	Insurance coverage influences patient access and volume

Historical Revenue Data:

• In 2010, Naprosyn/naproxen had global sales estimated at $600 million, predominantly driven by US prescription and OTC segments[3].
• Post-patent expiry, revenues declined marginally, stabilizing around $300-400 million annually in the US, with growth from emerging markets.

2. Competitive Dynamics

Competitor	Market Share (est.)	Key Differentiators	Pricing Strategy
Brand: Aleve (Bayer)	~20–25%	OTC prominence, wide consumer base	Premium, OTC pricing
Generics	50–60%	Price competitiveness	Lower price point
Celecoxib (Celebrex)	Niche market (~15%)	COX-2 selectivity reduces GI risks	Higher price, specialized use

3. Regulatory and Legal Environment

• Increasing regulatory scrutiny over NSAID safety (cardiovascular and gastrointestinal risks) influences prescribing behaviors[4].
• Litigation over adverse events impacts market perceptions and may impose financial liabilities on manufacturers.

4. Cost and Margin Dynamics

Cost Element	Trend	Impact
Raw Materials (e.g., propionic acid derivatives)	Fluctuating due to supply chain cycles	Affects manufacturing costs
R&D for Novel Formulations	Moderate investment; focused on safety	Potential for premium pricing and market expansion

---

What Are the Future Financial Projections for Naprosyn?

1. Revenue Forecasts

Year	Estimated Global Revenue	Key Drivers	Assumptions
2023	~$400 million	Steady demand, generic competition continues	Slight decline due to safety concerns and alternatives
2025	~$350–$420 million	Market penetration, OTC sales, incremental innovations	Stabilization with gradual growth in emerging markets
2028	~$400–$450 million	Market maturation, biosimilars, novel formulations	Potential resurgence via new formulations or combination therapies

2. Impact of Biosimilars and New Therapies

While biosimilars are primarily impacting biologics, their entry into inflammatory diseases (e.g., biosimilar biologics for rheumatoid arthritis) indirectly affects NSAID use patterns, possibly reducing peak revenues but expanding total analgesic market size.

3. Revenue Growth Factors

• Market penetration in emerging markets: BRIC nations and Southeast Asia are experiencing increased NSAID adoption.
• Product lineage expansion: New formulations aimed at reducing side effects may command premium pricing.
• Regulatory approvals: Fast-track approvals for safe, innovative formulations could catalyze growth.

---

How Do Competition and Policy Shape Naprosyn’s Future?

Strategic Consideration	Implication for Naprosyn	Actions for Stakeholders
Patent cliff effects	Increased generics, lower margins	Innovate with formulations or indications
Regulatory safety mandates	Potential restrictions or label updates	Invest in safety profiling and patient education
Market diversification	Entry into pain management niches	Emphasize value propositions in emerging markets

---

Comparison with Key NSAID Players

Parameter	Naprosyn (Naproxen)	Ibuprofen	Celecoxib (Celebrex)	Diclofenac
Approval Year	1976	1969	1998	1973
Brand Examples	Naprosyn, Aleve (OTC)	Advil, Motrin	Celebrex	Voltaren, Cambia
Market Segment	Widely used, balanced prescription/ OTC	OTC dominance	Prescription/Niche	Prescription, OTC
Safety Profile	Concerns over GI and CV risks	Generally safe, higher GI risk	Lower GI risk, CV risks	GI and CV risks
Pricing Strategy	Mix of premium branded and generics	Low-cost OTC	Premium (branded only)	Mid-range, generic available

---

Deep-Dive: Regulatory and Policy Impact on Revenue

Regulatory Aspect	Effect on Market	Examples	Timeline	Comments
FDA Safety Announcements	Sales slowdown, reformulations	2005 gastrointestinal safety warning	Ongoing	Leads to formulation innovations
EU Medicinal Agency Policies	Label updates, usage restrictions	Cardiovascular risk assessments	2010s	Affects prescriber confidence
Reimbursement Policy Changes	Affects sales volume	US Medicaid drug rebates	2010s	Cashflow impacts for manufacturers

---

Key Takeaways

• Market opportunities lie in expanding use cases, formulations, and geographical markets, especially in emerging economies.
• Patent expirations and generic competition pressure margins but expand volume; innovation remains critical.
• Safety concerns and regulatory scrutiny influence prescribing patterns and product development.
• Emerging biologics and biosimilars indirectly influence NSAID market share dynamics.
• Continued investment into formulation innovations and safety improvements can sustain revenue streams.

---

FAQs

Q1: How does patent expiry affect Naprosyn’s market revenue?
Patent expiry typically leads to increased generic competition, reducing unit prices and overall revenue for branded formulations. However, volume sales often increase due to lower prices, partially offsetting revenue declines.

Q2: What are the main safety concerns linked to Naprosyn?
NSAIDs like Naprosyn are associated with gastrointestinal ulcers, bleeding, cardiovascular risks (e.g., hypertension, myocardial infarction), and renal impairment. These concerns influence prescriber decisions and regulatory policies.

Q3: How are emerging markets impacting Naprosyn sales?
Growing healthcare infrastructure, rising income levels, and increasing prevalence of inflammatory diseases are expanding NSAID use in regions like Asia and Latin America, offering potential for market growth.

Q4: What role do OTC sales play in Naprosyn’s financial outlook?
OTC sales significantly contribute to revenue, providing volume growth and brand visibility, especially through products like Aleve. Regulatory approvals for OTC formulations facilitate wider accessibility.

Q5: Are there new formulations or alternative therapies threatening Naprosyn’s market?
Yes. Novel NSAID formulations with improved safety profiles and biological therapies (e.g., biologics for rheumatoid arthritis) are competitors that may reduce demand for traditional NSAIDs over time.

---

References

1. MarketsandMarkets. “NSAID Market by Product, Application, Route of Administration and Region - Global Forecast to 2028,” 2022.
2. GBD 2019 Disease and Injury Incidence and Prevalence Collaborators. “Global burden of musculoskeletal disorders,” The Lancet Rheumatology, 2019.
3. IMS Health. “Pharmaceuticals Market Report,” 2010.
4. U.S. Food and Drug Administration. “FDA Drug Safety Communications,” 2005–2022.

---

In conclusion, Naprosyn’s market remains resilient amid shifting dynamics. While patent cliffs and safety issues introduce challenges, opportunities in emerging markets, innovative formulations, and expanded use cases can sustain its financial trajectory. Stakeholders should proactively monitor regulatory developments, competitive innovations, and evolving prescribing behaviors to optimize positioning.